Long-term infliximab treatment in rheumatoid arthritis: Subsequent outcome of initial responders

Rheumatology

Volumn 46, Issue 7, 2007, Pages 1153-1156

  Buch, M H ^a   Bingham, S J ^a   Bryer, D ^a   Emery, P ^a  

^a CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

Infliximab; Outcome; RA; Response

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; VASCULITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS INDICATORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447336406     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem075     Document Type: Article

References (10)

1. Lipsky PE, van Der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment rheumatoid arthritis Anti-tumour necrosis factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
2. Smolen JS, Van der Heijde DM, St Clair EW et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dRse methotrexate with or without concomitant: Infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
3. Agarwal SK, Maier AL, Chibnik LB et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005;53:872-8.
4. Amett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
5. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Guidelines for prescribing TNF-α blockers in adults with RA. London: British Soceity for Rheumatology, June 2001.
6. Prevoo ML, van't Hof M, Kuper HH, van Leeuwen M, van de Putte LBA, van Riel P. Modified disease activity scores that includes twenty-eight joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
7. Bingham SJ, Buch MH, Kerr MA, Emery P, Valadao Barcelos AT. Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthritis Rheum 2004;50:4072-3.
8. Choy E, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
9. Buch MH, Dryer B, Lindsay S, Rees-Evans B, Fairclough A, Emery P. Shortening infusion times for infliximab administration. Rheumatology 2006;45:485-6.
10. Quinn MA, Conaghan PG, O'Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27-35.